Targeting of Prosurvival Pathways as Therapeutic Approaches against Primary Effusion Lymphomas: Past, Present, and Future

Figure 1

Effect of Bortezomib (BZ) (Santa Cruz) or Bay11-7082 (BAY) (Santa Cruz) on BC3 and BCBL1 PEL cells. (a) Effect on NF-κB p65 nuclear localization of Bortezomib in BC3 cells, in comparison to the untreated control cells, analyzed by immunofluorescence assay (IFA). A representative experiment out of three is shown. (b and c) Trypan blue exclusion assays of BC3 and BCBL1 PEL cells treated for 24 hours with Bortezomib (BZ) or Bay11-7082 (BAY), at the indicated doses. The mean ± SD of three independent experiments is reported.

(a)

(b)

(c)